Cubist Systematic Strategies LLC Buys New Shares in Tyra Biosciences, Inc. (NASDAQ:TYRA)

Cubist Systematic Strategies LLC acquired a new stake in shares of Tyra Biosciences, Inc. (NASDAQ:TYRA - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 109,748 shares of the company's stock, valued at approximately $1,526,000. Cubist Systematic Strategies LLC owned approximately 0.22% of Tyra Biosciences as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. KLP Kapitalforvaltning AS acquired a new stake in Tyra Biosciences in the 4th quarter valued at $31,000. US Bancorp DE acquired a new stake in shares of Tyra Biosciences in the 4th quarter worth about $50,000. BNP Paribas Financial Markets bought a new position in Tyra Biosciences in the 4th quarter valued at about $60,000. Aquatic Capital Management LLC bought a new position in shares of Tyra Biosciences in the fourth quarter valued at approximately $64,000. Finally, Wells Fargo & Company MN raised its holdings in shares of Tyra Biosciences by 51.7% in the fourth quarter. Wells Fargo & Company MN now owns 9,493 shares of the company's stock valued at $132,000 after purchasing an additional 3,236 shares during the last quarter. Institutional investors own 84.14% of the company's stock.

Tyra Biosciences Price Performance

Shares of TYRA traded up $0.13 during trading hours on Friday, hitting $9.99. The company's stock had a trading volume of 145,379 shares, compared to its average volume of 260,851. The business has a 50 day simple moving average of $9.57 and a two-hundred day simple moving average of $12.90. Tyra Biosciences, Inc. has a 52-week low of $6.42 and a 52-week high of $29.60. The company has a market cap of $530.37 million, a price-to-earnings ratio of -6.20 and a beta of 1.17.

Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.47) EPS for the quarter, beating the consensus estimate of ($0.49) by $0.02. Research analysts predict that Tyra Biosciences, Inc. will post -1.57 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on TYRA shares. Wedbush reiterated an "outperform" rating and set a $30.00 target price on shares of Tyra Biosciences in a research note on Friday, March 28th. HC Wainwright restated a "buy" rating and set a $30.00 price objective on shares of Tyra Biosciences in a report on Monday, March 31st. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Tyra Biosciences presently has an average rating of "Buy" and an average price target of $30.83.

Tyra Biosciences Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.